Can the Gupta siblings solve Lupin's US puzzle?

The US has been a sore point in the pharma company’s business. A turnaround is in the works.Lupin’s US revenue has shrunk while its margins are the worst among pharma companies. A series of setbacks—regulatory troubles, price erosion and impairments—have impacted the company.

Related Keywords

Tarapur ,Maharashtra ,India ,Australia ,Japan ,France ,Brazil ,Palghar ,Madhya Pradesh ,Southern Cross ,Victoria ,French ,Japanese ,Australian ,Desh Bandu ,Manju Gupta ,Ramesh Swaminathan ,Desh Bandhu ,Novel Laboratories Inc ,Bausch Medical Companies Inc ,Southern Cross Pharmaceuticals ,Drug Administration ,Gavis Pharmaceuticals ,Symbiomix Therapeutics ,World Health Organization ,Boehringer Ingelheim ,Novel Laboratories ,Nilesh ,Vinitha ,Lupin ,Us ,Desh Bandu Gupta ,Lupin Ltd ,Us Market ,Pharmaceuticals ,Fda ,